Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Objective To summarize the clinical characteristics and immunological and genetic features of patients who developed autoimmune polyendocrine syndrome type II (APS-2) after treatment with immune checkpoint inhibitors (ICIs).Design and methods Several databases (MEDLINE/EMBASE/Cochrane) were searched for studies published between January 2000 and February 2020 involving patients with two or more endocrine disorders after ICI therapy.Results Our final review included 22 articles comprising 23 patients (median age 56 years; 65.2% male patients). Of these patients, 60.9% received anti-programmed cell death 1 (PD-1) therapy, 17.4% received anti-programmed cell death ligand 1 (PD-L1) therapy, and 4.3% received anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monotherapy. Patients underwent a median of four treatment cycles before the onset of the primary adverse event; the median time of onset was 8.5 weeks. Endocrine organs affected by ICI administration included the thyroid gland (18/23, 78.3%), pancreatic islets (17/23, 73.9%), pituitary gland (11/23, 47.8%), and adrenal gland (2/23, 8.7%). Related autoantibodies were detected in 65.2% of patients. In patients with diabetes, glutamic acid decarboxylase antibody was closely related to the development of diabetes ketoacidosis. The human leukocyte antigen genotype was reported in 34.8% (8/23) of patients, 5 (62.5%) of which had risk genotypes.Conclusions As a serious adverse event of ICI treatment, APS-2 is presented with abrupt initiation time and rapid development. Physicians should be aware of potential endocrine disorders and continue monitoring hormone status when treating cancer patients with ICIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fulminant onset of type 1 diabetes can occur, with DKA and low or undetectable levels of C-peptide as a marker of endogenous b -cell function (64 -66).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [65]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is still unclear if steroid-sparing regimens decrease the risk of PTDM with studies showing mixed results.1591–1595”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1591]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Baekkeskov, S., Aanstoot, H.-J., Christgai, S., Reetz, A., Solimena, M., Cascalho, M., Folli, F., Richter-Olesen, H., & Camilli, P.-D. (1990) · Nature · doi:10.1038/347151a0 · Cited by 1,964
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., & Goldhirsch, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30261-4 · Cited by 973
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 939
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Self-citationAutosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B.-S., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 832
HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk
Erlich, H., Valdes, A. M., Noble, J., Carlson, J. A., Varney, M., Concannon, P., Mychaleckyj, J. C., Todd, J. A., Bonella, P., Fear, A. L., et al. (2008) · Diabetes · doi:10.2337/db07-1331 · Cited by 790
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659
Toxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 650
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 558
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Khunger, M., Rakshit, S., Pasupuleti, V., Hernandez, A. V., Mazzone, P., Stevenson, J., Pennell, N. A., & Velcheti, V. (2017) · Chest · doi:10.1016/j.chest.2017.04.177 · Cited by 502
Autoimmune Polyendocrine Syndromes
Husebye, E. S., Anderson, M. S., & Kämpe, O. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1713301 · Cited by 466
Suresh, K., Voong, K. R., Shankar, B., Forde, P. M., Ettinger, D. S., Marrone, K. A., Kelly, R. J., Hann, C. L., Levy, B., Feliciano, J. L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2035 · Cited by 434
21-hydroxylase, a major autoantigen in idiopathic Addison's disease
Winqvist, O., Karlsson, F. A., & Kämpe, O. (1992) · The Lancet · doi:10.1016/0140-6736(92)91829-w · Cited by 410
Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0402 · Cited by 395
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
Czarnocka, B., Ruf, J., Ferrand, M., Carayon, P., & Lissitzky, S. (1985) · FEBS Letters · doi:10.1016/0014-5793(85)80446-4 · Cited by 367
Duan, J., Cui, L., Zhao, X., Bai, H., Cai, S., Wang, G., Zhao, Z., Zhao, J., Chen, S., Song, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5367 · Cited by 349
Self-citationRheumatic immune-related adverse events from cancer immunotherapy
Calabrese, L. H., Calabrese, C., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 233
Xing, P., Zhang, F., Wang, G., Xu, Y., Li, C., Wang, S., Guo, Y., Cai, S., Wang, Y., & Li, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0779-6 · Cited by 176
Ascierto, P. A., Simeone, E., Sileni, V., Pigozzo, J., Maio, M., Altomonte, M., Del Vecchio, M., Di Guardo, L., Marchetti, P., Ridolfi, R., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-116 · Cited by 163
Awatal, T., Kuzuyal, T., Matsuda, A., Iwamoto, Y., & Kanazawa, Y. (1992) · Diabetologia · doi:10.1007/bf02342437 · Cited by 133
Kim, H. I., Kim, M., Lee, S.-H., Park, S. Y., Kim, Y. N., Kim, H., Jeon, M. J., Kim, T. Y., Kim, S. W., Kim, W. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1375642 · Cited by 123
Yasunaga, S., Kimura, A., Hamaguchi, K., Rønningen, K. S., & Sasazuki, T. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02512.x · Cited by 111
Lowe, J. R., Perry, D. J., Salama, A. K. S., Mathews, C. E., Moss, L. G., & Hanks, B. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0196-z · Cited by 109
Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma
Paepegaey, A.-C., Lheure, C., Ratour, C., Lethielleux, G., Clerc, J., Bertherat, J., Kramkimel, N., & Groussin, L. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00170 · Cited by 102
Hansen, E., Sahasrabudhe, D. M., & Sievert, L. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1835-4 · Cited by 93
Hashimoto, K., Maruyama, H., Nishiyama, M., Asaba, K., Ikeda, Y., Takao, T., Iwasaki, Y., Kumon, Y., Suehiro, T., Tanimoto, N., et al. (2005) · Hormone Research in Paediatrics · doi:10.1159/000089293 · Cited by 69
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
Lupi, I., Brancatella, A., Cosottini, M., Viola, N., Lanzolla, G., Sgrò, D., Dalmazi, G. D., Latrofa, F., Caturegli, P., & Marcocci, C. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0102 · Cited by 69
Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
Lanzolla, G., Coppelli, A., Cosottini, M., Prato, S. D., Marcocci, C., & Lupi, I. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00366 · Cited by 63
Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.244.33 · Cited by 52
Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab
Li, L., Masood, A., Bari, S., Yavuz, S., & Grosbach, A. B. (2017) · Case Reports in Oncology · doi:10.1159/000456540 · Cited by 42
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
Hakami, O. A., Ioana, J., Ahmad, S., Tun, T. K., Sreenan, S., & McDermott, J. H. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0153 · Cited by 39
Marchand, L., Paulus, V., Fabien, N., Pérol, M., Thivolet, C. H., Vouillarmet, J., & Saintigny, P. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.021 · Cited by 36
Gunjur, A., Klein, O., Kee, D., & Cebon, J. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0713-y · Cited by 36
Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
Tzoulis, P., Corbett, R., Ponnampalam, S., Baker, E., Heaton, D., Doulgeraki, T., & Stebbing, J. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0111 · Cited by 34
Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes
Kong, S. H., Lee, S. Y., Yang, Y., Kim, T. M., & Kwak, S. H. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0872-y · Cited by 30
Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment
León, J., Capel, I., Bonfill, T., Mazarico, I., Casamitjana, L., Caixàs, A., & Rigla, M. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0045 · Cited by 29
A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment
Humayun, M. A., & Poole, R. (2016) · HORMONES · doi:10.14310/horm.2002.1656 · Cited by 28
Okahata, S., Sakamoto, K., Mitsumatsu, T., Kondo, Y., Noso, S., Ikegami, H., & Shiba, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0328 · Cited by 25
Kurihara, S., Oikawa, Y., Nakajima, R., Satomura, A., Tanaka, R., Kagamu, H., & Shimada, A. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13212 · Cited by 24
Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
Patel, S., Chin, V. T., & Greenfield, J. R. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0098 · Cited by 21
Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency
Machado, C. M., Santos, L. A., Barroso, A., & Oliveira, M. J. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-231236 · Cited by 19
Immune-related endocrine disorders in novel immune checkpoint inhibition therapy
Min, L. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.10.002 · Cited by 16
Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
Shaaban, H. S., Kuru, S., & Khan, N. H. (2017) · International Journal of Critical Illness and Injury Science · doi:10.4103/ijciis.ijciis_15_17 · Cited by 14
Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis
Sum, M., & Vallejo, F. (2018) · Pituitary · doi:10.1007/s11102-018-0880-8 · Cited by 11
Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature
Aziz, K., Shahbaz, A., Umair, M., & Sachmechi, I. (2018) · EXCLI journal · doi:10.17179/excli2018-1357 · Cited by 7
A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
Erra, A., Pannu, B. S., Patel, S., Qureshi, F. M., & Soliman, M. (2019) · Cureus · doi:10.7759/cureus.5001 · Cited by 6
Research works printed but not linked: 1
- Schmidt MB. Eine biglandulare Erkrankung (Nebennieren und Schilddruse bei Morbus Addisonni) Dtsch Pathol Ges. 1926;21:212–221. [Google Scholar]
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Metadata
- Authors
- Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Zhang, Dan
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2020-11-16
- Volume
- 70
- Issue
- 6
- Pages
- 1527-1540
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC10992261
- OpenAlex
- W3103624149
- Cited by
- 30
- References
- 60
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 5
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Sciences Foundation of China (81630097, 81773718)
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-I2M-3-011)
- Chinese Academy of Medical Sciences Fundamental Research Funds for the Central Universities (2018RC350002)
- Drug Innovation Major Project (2018ZX09711001-003-005, 2018ZX09711001-008-005, 2018ZX09711001-003-020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, thyroid dysfunction, pancreatic islet autoimmunity, pituitary dysfunction, adrenal insufficiency, autoantibodies, glutamic acid decarboxylase antibodies, diabetic ketoacidosis, endocrine disorders
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Polyendocrinopathies, Autoimmune
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.